protein inhibitor of activated STAT 4Genealiases: PIAS-gamma · PIASY · Piasg · ZMIZ6
Q-omics provides the consensus-scored PIAS4 profile across patient tissues and cancer cell-line models. PIAS4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PIAS4 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, PIAS4 protein abundance shows 21,836 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where PIAS4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PIAS4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PIAS4 survival associations across molecular data types. PIAS4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PIAS4 RNA expression–survival associations across cancer types. High PIAS4 expression shows unfavorable associations in ACC and MESO, but favorable associations in SCLC, HNSC, KIRC and UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PIAS4 RNA expression.
This table summarizes PIAS4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PIAS4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PIAS4 shows higher tumor expression in HNSC, KIRC, BLCA, LIHC, LUSC and COAD. The HNSC box plot shows higher PIAS4 RNA expression in tumor versus normal tissue (log2 FC = +1.026, t-test p < 0.001).
This table shows molecular features associated with PIAS4 in patient tissues and cancer cell lines. In patient samples, PIAS4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PIAS4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
